The duke afm program intensive induction chemotherapy for metastatic breast cancer
The duke afm program intensive induction chemotherapy for metastatic breast cancer
复制标题
杜克 afm 计划针对转移性乳腺癌的强化诱导化疗
作者:
PhD MD Roy B. Jones;MD Elizabeth J. Shpall;MD Jeffrey Shogan;RN Msn Mary Lou Affronti;Rpa David Coniglio;MD Lowell Hart;MD Edward Halperin;MD J. Dirk Iglehart;MD Joseph Moore;MD Jon Gockerman;MD Robert C. Bast;MD William P. Peters;MD Columbia William Babcock;MD SC Kamal Bakri
Forty‐five patients have completed treatment with AFM, an intensive induction chemotherapy regimen composed of Adriamycin (doxorubicin, Adria Laboratories, Columbus, Ohio), 5‐fluorouracil, and methotrexate with folinic acid rescue. This regimen was designed to produce rapid and extensive tumor shrinkage prior to high‐dose alkylating agent chemotherapy with autologous marrow support. The overall response rate was 91%, and 38% of patients achieved complete clinical responses after a mean of 70 days on treatment. Hematologic and mucosal toxicity were extensive, but no toxic deaths were noted. AFM is a potent remission induction regimen for metastatic breast cancer, but its considerable toxicity suggests caution in its use for routine breast cancer treatment.
登录
查看更多内容
影响因子:
6.6
作者:
STERNBERG, CN;YAGODA, A;WHITMORE, WF
通讯作者:
WHITMORE, WF
影响因子:
11.2
作者:
Einhorn,LH
通讯作者:
Einhorn,LH
DOI:
--
发表时间:
1981
期刊:
Cancer treatment reports
影响因子:
--
作者:
Gale,RP
通讯作者:
Gale,RP
DOI:
10.1200/jco.1987.5.2.172
发表时间:
1987
期刊:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子:
--
作者:
Jones,RB;Holland,JF;Bhardwaj,S;Norton,L;Wilfinger,C;Strashun,A
通讯作者:
Strashun,A
影响因子:
158.5
作者:
BRANDT, SJ;PETERS, WP;OETTE, DH
通讯作者:
OETTE, DH